Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Brunswick, GA

    Search
    Brunswick, GA
    Show Map
    Map View
    Brunswick, GA

    Popular Searches

    By Condition

    Depression Clinical Trials in Georgia

    Anxiety Clinical Trials in Georgia

    Schizophrenia Clinical Trials in Georgia

    ADHD Clinical Trials in Georgia

    Bipolar Disorder Clinical Trials in Georgia

    Multiple Sclerosis Clinical Trials in Georgia

    Autism Clinical Trials in Georgia

    Treatment Resistant Depression Clinical Trials in Georgia

    Borderline Personality Disorder Clinical Trials in Georgia

    Social Anxiety Disorder Clinical Trials in Georgia

    Parkinson's Disease Clinical Trials in Georgia

    Alzheimer's Disease Clinical Trials in Georgia

    By Location

    Clinical Trials near Atlanta, GA

    Clinical Trials near Augusta, GA

    Clinical Trials near Decatur, GA

    Clinical Trials near Savannah, GA

    Clinical Trials near Marietta, GA

    Clinical Trials near Columbus, GA

    Clinical Trials near Macon, GA

    Clinical Trials near Lawrenceville, GA

    Clinical Trials near Gainesville, GA

    Clinical Trials near Athens, GA

    Clinical Trials near Roswell, GA

    Clinical Trials near Stockbridge, GA

    Other People Viewed

    By Subject

    194 Clinical Trials near East Brunswick, NJ

    Top Clinical Trials near New Brunswick, NJ

    203 Clinical Trials near Conyers, GA

    221 Clinical Trials near Covington, GA

    208 Clinical Trials near Evans, GA

    207 Clinical Trials near Augusta, GA

    Top Clinical Trials near Dalton, GA

    Top Clinical Trials near Cordele, GA

    Top Clinical Trials near Cartersville, GA

    Top Clinical Trials near Canton, GA

    Top Clinical Trials near Austell, GA

    Top Clinical Trials near Adairsville, GA

    By Trial

    Automatic Tube Compensation vs. Pressure Support Ventilation for Weaning From Mechanical Ventilation

    Investigational Scan for Brain Tumor Recurrence

    Decision Support Tool for Prediabetes

    Infliximab for Aneurysms

    MRI for Brain Tumor Detection After Radiation

    Alpha-Stim AID + Life Coaching for Mental Health Disorders

    Resistance Training + Protein Supplementation for Pancreatic Cancer

    EPA and DHA for Lipid Disorders

    KB801 for Keratitis

    Decitabine + Lisaftoclax + Olverembatinib for Leukemia

    Saline Infusion for Chronic Fatigue Syndrome

    Youth-led Intervention for Cancer Screening

    Related Searches

    Top Clinical Trials near Bryan, TX

    Top Clinical Trials near Buckley, MI

    Mentoring for Cardiovascular Health

    Remote Monitoring for Type 2 Diabetes

    PET/MR Imaging for Cardiac Arrhythmias

    Autologous Muscle Derived Cells for Swallowing Disorders

    Injectable Cabotegravir for HIV Prevention

    CBD for Traumatic Brain Injury

    ECC5004 for Type 2 Diabetes

    Juveena Hydrogel System for Menorrhagia

    Olutasidenib + Venetoclax + Azacitidine for Acute Myeloid Leukemia

    Autologous Skin Grafts for Wounds and Injuries

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      213 Clinical Trials near Brunswick, GA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Levocarnitine for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma

      Jacksonville, Florida
      This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:15 - 40

      Key Eligibility Criteria

      Disqualifiers:Down Syndrome, Severe Liver Fibrosis, Others
      Must Be Taking:Asparaginase

      440 Participants Needed

      N-acetylcysteine for Retinitis Pigmentosa

      Jacksonville, Florida
      This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Active Cancer, Renal Failure, Liver Disease, Others

      483 Participants Needed

      Tecovirimat for Monkeypox

      Jacksonville, Florida
      A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Risk, Others
      Must Not Be Taking:Tecovirimat, Cabotegravir/Rilpivirine

      719 Participants Needed

      Efgartigimod for Myositis

      Jacksonville, Florida
      This trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Autoimmune Disease, Malignancy, Others

      265 Participants Needed

      Long-term Remibrutinib for Chronic Hives

      Savannah, Georgia
      This trial tests remibrutinib, a medication for adults with chronic hives not helped by standard treatments. It aims to see if remibrutinib can reduce symptoms by blocking signals that cause hives. Remibrutinib is a highly selective, oral medication that has shown promising efficacy and safety in treating chronic spontaneous urticaria.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Bleeding Risk, Hepatic Disease, Others
      Must Not Be Taking:Anti-platelets, Anticoagulants

      696 Participants Needed

      Leuprolide for Precocious Puberty

      Jacksonville, Florida
      The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2 - 9

      Key Eligibility Criteria

      Disqualifiers:Peripheral Precocious Puberty, Intracranial Tumor, Diabetes, Others
      Must Not Be Taking:GnRH, Medroxyprogesterone, Growth Hormone, IGF-1

      93 Participants Needed

      ECLIPSE PV / A22-203

      Jacksonville, Florida
      This trial tests a medication called ropeginterferon alfa-2b-njft in adults with polycythemia vera, a type of blood cancer. The goal is to see how well it works and how safe it is. The medication helps the immune system control abnormal blood cells to prevent serious health issues. Ropeginterferon alfa-2b is a new form of treatment recently shown to be safe and effective in polycythemia vera.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Diseases, Severe Retinopathy, Depression, Others
      Must Not Be Taking:Interferon Alfa

      111 Participants Needed

      COVID-19 Vaccine for Children

      Jacksonville, Florida
      This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart and NVX CoV2373 or a variant-based vaccine given as a booster dose or at crossover in pediatric participants (3 age cohorts; 6 to \< 12 years, 2 to \< 6 years, and 6 to \< 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to \< 12 years of age).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:6 - 11

      Key Eligibility Criteria

      Disqualifiers:COVID-19 History, Immunodeficiency, Cancer, Others
      Must Not Be Taking:COVID-19 Treatments

      3600 Participants Needed

      Oral Contraceptive for Birth Control

      Savannah, Georgia
      This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The secondary objective of Part A is to evaluate the safety and tolerability of LPRI-CF113. The primary objective of Part B is to evaluate the impact of LPRI-CF113 on bone mineral density (BMD) at the lumbar spine (L1-L4) after 12 months (13 medication cycles). The secondary objective of Part B is to evaluate the impact of LPRI-CF113 on BMD and bone turnover after 12 months (13 medication cycles) at the femoral neck, total hip, and total body.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:13 - 45
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Amenorrhea, Thromboembolism, Others
      Must Not Be Taking:Barbiturates, Anticonvulsants, Rifampin, Others

      1009 Participants Needed

      Stem Cell Transplantation for Leukemia

      Jacksonville, Florida
      This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 21

      Key Eligibility Criteria

      Disqualifiers:Genetic Disorders, Pregnancy, Uncontrolled Infections, Others

      435 Participants Needed

      Mirvetuximab + Bevacizumab for Ovarian Cancer

      Jacksonville, Florida
      GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Other Cancers, Cardiac Disease, Infections, Others
      Must Be Taking:Platinum-based Chemotherapy

      520 Participants Needed

      Sodium Thiosulfate for Hearing Loss in Medulloblastoma

      Jacksonville, Florida
      This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:4 - 21

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Pregnancy, Others
      Must Not Be Taking:Anticonvulsants, Thiol Agents

      225 Participants Needed

      Chemotherapy for Rhabdomyosarcoma

      Jacksonville, Florida
      This trial uses chemotherapy drugs to treat patients with very low-risk and low-risk rhabdomyosarcoma. The goal is to maintain good outcomes while reducing treatment intensity. The study also examines if patients with specific DNA mutations benefit from more intensive therapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:< 21

      Key Eligibility Criteria

      Disqualifiers:Prior Chemotherapy, Radiation, Uncontrolled Infection, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Inducers

      205 Participants Needed

      Depemokimab for Severe Asthma

      Savannah, Georgia
      This trial is testing Depemokimab, a medication for people with severe asthma that doesn't respond well to usual treatments. It works by reducing specific cells that cause airway inflammation, aiming to improve breathing and reduce symptoms.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Malignancy, Uncontrolled Cardiovascular, Liver Disease, Others

      641 Participants Needed

      Thoracotomy vs Thoracoscopy for Metastatic Osteosarcoma

      Jacksonville, Florida
      This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:< 50

      Key Eligibility Criteria

      Disqualifiers:Unresectable Tumor, Central Lesions, Others
      Must Be Taking:Cisplatin-doxorubicin, Ifosfamide

      250 Participants Needed

      BI 907828 vs Doxorubicin for Liposarcoma

      Jacksonville, Florida
      This trial is for adults with advanced dedifferentiated liposarcoma who are not receiving other treatments. It compares a new drug, brigimadlin (BI 907828), which blocks a protein that helps cancer grow, with doxorubicin, an existing drug that damages cancer cell DNA. Participants receive either brigimadlin as tablets or doxorubicin through a vein. Doctors monitor tumor size and health regularly. The new drug aims to be effective and less toxic compared to conventional treatments.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:TP53 Mutation, Other Malignancies, Others
      Must Not Be Taking:Anthracyclines

      400 Participants Needed

      Rimegepant for Migraine Prevention in Children

      Savannah, Georgia
      This trial is testing rimegepant, a medication that prevents migraines, in children and teens who have occasional migraines. It works by blocking a protein that causes migraine pain. Rimegepant is taken orally and has shown effectiveness in treating migraines.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Basilar Migraine, Cluster Headaches, Hemiplegic Migraine, Psychiatric Disorder, Substance Abuse, Others

      640 Participants Needed

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      Jacksonville, Florida
      This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors

      800 Participants Needed

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      Savannah, Georgia
      This trial compares remibrutinib and teriflunomide in patients with relapsing multiple sclerosis. It aims to find out which medication is more effective and safer. Both drugs work by controlling the immune system to reduce relapses. Teriflunomide is an approved treatment for adults with this condition.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors, Others

      800 Participants Needed

      Evogliptin for Aortic Stenosis

      Jacksonville, Florida
      This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:35+

      Key Eligibility Criteria

      Disqualifiers:Severe Valve Disease, Heart Failure, Diabetes, Others
      Must Not Be Taking:DPP4 Inhibitors, Vitamin K, CYP3A4 Drugs

      580 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Trial

      Tucatinib + Trastuzumab + Pertuzumab for Breast Cancer

      Jacksonville, Florida
      This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastasis, Leptomeningeal Disease, Others
      Must Be Taking:Trastuzumab, Pertuzumab, Taxane

      654 Participants Needed

      Ianalumab + Standard Therapy for Lupus Nephritis

      Jacksonville, Florida
      This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Renal Impairment, Transplant History, Active Infections, Others
      Must Be Taking:Corticosteroids, MPA

      462 Participants Needed

      Tissue Kallikrein for Ischemic Stroke

      Jacksonville, Florida
      This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Hemorrhagic Stroke, Large Vessel Occlusion, MT, HAE, Others
      Must Not Be Taking:ACE Inhibitors, HAE Treatments

      728 Participants Needed

      Anti-Coagulant + Anti-Platelet Therapy for Stroke Prevention

      Jacksonville, Florida
      The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Intracranial Tumor, Cardiac Embolism, Others
      Must Not Be Taking:Thrombolytics, Antithrombotics, CYP3A4 Inhibitors

      1683 Participants Needed

      Combination Chemotherapy for Rhabdomyosarcoma

      Jacksonville, Florida
      This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in a class of medications called vinca alkaloids. They work by stopping cancer cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are chemotherapy medications that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or for the rest of patient's life.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:< 50

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, CNS Involvement, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Inducers

      118 Participants Needed

      Abemaciclib for Liposarcoma

      Jacksonville, Florida
      This trial is testing abemaciclib, a drug that blocks proteins helping cancer cells grow, in patients with advanced or spreading DDLS. The goal is to see if it can stop the cancer from getting worse.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Malignancies, Severe Medical Disease, Others
      Must Not Be Taking:CDK4 Inhibitors

      108 Participants Needed

      Memantine for Brain Tumor

      Jacksonville, Florida
      This trial tests whether memantine can help children and adolescents with brain tumors maintain their thinking abilities during treatment. Memantine may protect brain function by blocking certain parts of nerve cells that cause thinking problems. Memantine has been used to treat thinking issues in Alzheimer's disease and to prevent thinking problems in patients undergoing brain treatment.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Intractable Seizures, Neurodevelopmental Disorders, Others
      Must Not Be Taking:Anticonvulsants, Carbonic Anhydrase Inhibitors

      192 Participants Needed

      AGTC-501 for Retinitis Pigmentosa

      Jacksonville, Florida
      This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:12 - 50
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Herpes, Corticosteroid Allergy, Gene Therapy, Others
      Must Not Be Taking:Anticoagulants, Corticosteroids

      85 Participants Needed

      Atropine Eye Drops for Near-Sightedness

      Jacksonville, Florida
      This trial is testing special eye drops with a tiny amount of atropine to see if they can slow down worsening nearsightedness in children. The drops work by relaxing eye muscles and slowing down changes in the eye. Lower doses of atropine have shown effectiveness with fewer side effects.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:3 - 15

      Key Eligibility Criteria

      Disqualifiers:Ocular Inflammation, Myopia Control Treatment, Refractive Surgery, Others

      678 Participants Needed

      Nivolumab + Chemo-Immunotherapy for Large B-Cell Lymphoma

      Jacksonville, Florida
      This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2+

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Infection, Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      244 Participants Needed

      1...345...8

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Brunswick, GA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Brunswick, GA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Brunswick, GA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Brunswick, GA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Brunswick, GA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Brunswick, GA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Brunswick, GA?

      Most recently, we added Pumitamig + Chemotherapy vs Nivolumab + Chemotherapy for Stomach Cancer, Abrocitinib for Eczema and Mirena for Endometrial Hyperplasia to the Power online platform.